Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study

被引：0

作者：

Qing Zhou

He-Long Zhang

Li-Yan Jiang

Yuan-Kai Shi

Yuan Chen

Jin-Ming Yu

Cai-Cun Zhou

Yong He

Yan-Ping Hu

Zong-An Liang

Yue-Yin Pan

Wen-Lei Zhuo

Yong Song

Gang Wu

Gong-Yan Chen

You Lu

Cui-Ying Zhang

Yi-Ping Zhang

Ying Cheng

Shun Lu

Chang-Li Wang

Jian-Ying Zhou

Yun-Peng Liu

Jian-Xing He

Jie Wang

Yi-Long Wu

机构：

[1] Guangdong Provincial People’s Hospital,Guangdong Lung Cancer Institute

[2] Guangdong Academy of Medical Sciences,Department of Oncology

[3] Tangdu Hospital,Department of Respiratory Medicine

[4] Fourth Military Medical University,Department of Medical Oncology

[5] Shanghai Chest Hospital,Department of Oncology

[6] Shanghai Jiao Tong University,Department of Radiation Oncology

[7] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology

[8] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Respiratory Medicine

[9] Tongji Hospital of Tongji Medical College,Department of Oncology

[10] Huazhong University of Science and Technology,Department of Respiratory and Critical Care Medicine, West China School of Medicine and West China Hospital

[11] Shandong Cancer Hospital Affiliated to Shandong University,Department of Oncology

[12] Shandong Academy of Medical Sciences,Department of Oncology

[13] Shanghai Pulmonary Hospital,Department of Respiration

[14] Tongji University,Cancer Center, Tongji Medical College

[15] Daping Hospital and the Research Institute of Surgery of the Third Military Medical University,Department of Respiration

[16] Hubei Cancer Hospital,Department of Thoracic Oncology, Cancer Center

[17] Sichuan University,Cancer Center

[18] Anhui Medical University,Department of Thoracic Medical Oncology

[19] Xinqiao Hospital,Department of Oncology

[20] The Third Military Medical University,Department of Shanghai Lung Cancer Center

[21] General Hospital of Eastern Theater Command of Chinese People’s Liberation Army,Department of Lung Cancer

[22] Union Hospital,Department of Respiratory Disease, Thoracic Disease Center, First Affiliated Hospital of College of Medicine

[23] Huazhong University of Science and Technology,Department of Medical Oncology

[24] Harbin Medical University Cancer Hospital,Department of Thoracic Surgery, Guangzhou Institute for Respiratory Health

[25] West China Hospital,undefined

[26] Sichuan University,undefined

[27] Inner Mongolia Autonomous Region People’s Hospital,undefined

[28] Zhejiang Cancer Hospital,undefined

[29] Jilin Cancer Hospital,undefined

[30] Shanghai Chest Hospital,undefined

[31] Shanghai Jiaotong University,undefined

[32] Tianjin Medical University Cancer Institute and Hospital,undefined

[33] Zhejiang University,undefined

[34] The First Hospital of China Medical University,undefined

[35] First Affiliated Hospital of Guangzhou Medical University,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Epidermal growth factor receptor; T790M; Non-small cell lung cancer; Osimertinib; Real-world;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：10771 / 10780

页数：9

共 60 条

[1] Ahn M-J(2019)Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies Cancer 125 892-901
[2] Tsai C-M(2018)Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial Cancer Sci 109 1930-1938
[3] Shepherd FA(2021)Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 Chin Med J 134 783-791
[4] Akamatsu H(2020)Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis Curr Med Res Opin 36 477-482
[5] Katakami N(2019)ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer Future Oncol 15 3003-3014
[6] Okamoto I(2021)Therapy of lung cancer in China: introducing the special collection Ther Adv Med Oncol 13 17588359211038200-1652
[7] Cao W(2016)Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study Lancet Oncol 17 1643-928
[8] Chen H-D(2008)Locally advanced non-small cell lung cancer: the past, present, and future J Thorac Oncol 3 917-303
[9] Yu Y-W(2017)Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer Asia Pac J Clin Oncol 13 296-652
[10] Cho BC(2019)Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing Future Oncol 15 637-122

← 1 2 3 4 5 6 →